Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the company had been expecting to last into the second quarter of 2026.

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Mayo Clinic's organoids, microscopic versions of organs that function like the real ones, have been used by doctors to study ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed  organoid models  to study  uveal melanoma , one of the most common types of eye cancer ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on CSTL stock, giving a Buy rating yesterday.Invest with Confidence: ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Immunocore Holdings (IMCR – Research Report), retaining the price target ...

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ...

D models of uveal melanoma are transforming cancer research, enabling personalized treatments and better drug testing for ...